BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8243570)

  • 1. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P; Wright LA; Milliken S; Biggs JC
    Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
    Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
    [No Abstract]   [Full Text] [Related]  

  • 8. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W
    Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W; Daskalakis M; Finke J; Dölken G
    FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of polymerase chain reaction for determining bcr/abl mRNA in human chronic myeloleukemia].
    Dominskiĭ DA; Pokrovskaia ES; Babushkina EA; Turkina AG; Grineva NI
    Genetika; 1994 Dec; 30(12):1636-9. PubMed ID: 7534246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H; Mills K; Gibson I
    Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia.
    Sooknanan R; Malek L; Wang XH; Siebert T; Keating A
    Exp Hematol; 1993 Dec; 21(13):1719-24. PubMed ID: 8243571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
    Martinelli G; Testoni N; Montefusco V; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazzi F; de Vivo A; Pane F; Rosti G; Tura S
    Haematologica; 1998 Jul; 83(7):593-601. PubMed ID: 9718863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA; Milliken S; Biggs JC; Kearney P
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
    Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
    Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
    Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W; Cantin EM; Finke J; Dölken G
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.